The role of autologous haematopoetic stem cell transplantation in post-remission therapy of AML

被引：0
|
作者：
Durakovic, N. [1 ]
Batinic, J. [1 ]
Sertic, D. [2 ]
Bojanic, I. [2 ]
Batinic, D. [1 ]
Golubic-Cepulic, B. [2 ]
Nemet, D. [1 ]
机构：
[1] Univ Zagreb, Sch Med, Zagreb 41001, Croatia
[2] Clin Hosp Ctr Zagreb, Zagreb, Croatia
来源：
BONE MARROW TRANSPLANTATION | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S392 / S393
页数：2
相关论文
共 50 条
  • [1] High-dose chemotherapy with autologous PDSCT as post-remission therapy for AML
    M Harada
    H Gondo
    F Kawano
    Bone Marrow Transplantation, 2001, 27 : 347 - 347
  • [2] High-dose chemotherapy with autologous PBSCT as post-remission therapy for AML
    Harada, M
    Gondo, H
    Kawano, F
    BONE MARROW TRANSPLANTATION, 2001, 27 (03) : 347 - 347
  • [3] Myeloablative therapy and autologous (ABMT) or allogeneic marrow transplantation (BMT) are equivalent post-remission therapy in acute myelogenous leukaemia (AML).
    Novitzky, N
    Thomas, V
    BLOOD, 1995, 86 (10) : 386 - 386
  • [4] Myeloablative therapy and autologous or allogeneic marrow and stem cell transplantation are equivalent post-remission therapies in acute myeloid leukaemia.
    Novitzky, N
    Thomas, V
    BLOOD, 1996, 88 (10) : 3834 - 3834
  • [5] Optimal post-remission consolidation therapy in patients with AML
    Jimenez-Chillon, Carlos
    Dillon, Richard
    Russell, Nigel
    ACTA HAEMATOLOGICA, 2024, 147 (02) : 148 - 159
  • [6] Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy
    Thomas, X
    Le, QH
    De Botton, S
    Raffoux, E
    Chelghoum, Y
    Pautas, C
    Dreyfus, F
    Dhedin, N
    Vekhoff, A
    Troncy, J
    Pigneux, A
    De Revel, T
    Reman, O
    Travade, P
    Thiebaut, A
    Guerci, A
    Elhamri, M
    Fenaux, P
    Dombret, H
    Michallet, M
    LEUKEMIA & LYMPHOMA, 2005, 46 (07) : 1007 - 1016
  • [7] Should older adults with AML receive post-remission therapy?
    Stone, Richard M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (2-3) : 106 - 111
  • [8] Superiority of autologous over allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after intensive chemotherapy
    Thomas, X
    Le, QH
    Fenaux, P
    Dombret, H
    Chelghoum, Y
    Pautas, C
    Dreyfus, F
    Stamatoullas, A
    Dhedin, N
    Troncy, J
    Pigneux, A
    Thiebaut, A
    Elhamri, M
    Michallet, M
    BONE MARROW TRANSPLANTATION, 2003, 31 : S172 - S172
  • [9] Comparison of post-remission strategies in acute myeloid leukemia: Autologous hematopoietic stem cell transplantation versus consolidation chemotherapy
    Yegin, Zeynep Arzu
    Dikyar, Asena
    Kaynar, Lale Aydin
    Can, Ferda
    Ozkurt, Zubeyde Nur
    Yagci, Munci
    HEMATOLOGY REPORTS, 2020, 12 (03) : 51 - 54
  • [10] Effective post-remission therapy with an autologous stem cell transplant (ASCT) for the ELN-favourable and intermediate-risk acute myeloid leukaemia (AML) patients
    Cerny, J.
    Ramanathan, M.
    Raffel, G.
    Evens, A.
    Walsh, W.
    Fortier, N.
    Shanahan, L.
    Bednarik, J.
    Rosmarin, A.
    Nath, R.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S538 - S539
12345